Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry.

By M. Freeman, J. Hibbeln, K. Wisner, John M. Davis, D. Mischoulon, M. Peet, P. Keck, L. Marangell, A. Richardson, J. Lake and 1 more. Journal of Clinical Psychiatry, 2006

751 citations recorded by the source corpus.

Subfields: Biochemistry, Biological Psychiatry, Nutrition and Dietetics

View Paper: https://www.semanticscholar.org/paper/4cd056cd7a41d7fc0c6b23e152684c82fa79d1ed

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Biochemistry

1. C. Stanton
2. R. Ross
3. P. Calder
4. I. Djuricić
5. M. Rogero

In Biological Psychiatry

1. C. Stanton

In Nutrition and Dietetics

1. C. Stanton
2. R. Ross
3. P. Calder
4. I. Djuricić
5. M. Rogero

Citations in the corpus

• Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines (2015, methodology): “Two meta-analyses, each of eight RCTs (seven common to both) found a significant benefit versus placebo (Appleton et al., 2006; Freeman et al., 2006) (ES 0.”
• Mechanisms of action of (n-3) fatty acids. (2012, background): “Very long-chain (n-3) fatty acids may contribute to enhanced mental development (28) and improved childhood learning and behavior (29) and may lower the burden of psychiatric illnesses in adults (30).”
• Health Implications of High Dietary Omega-6 Polyunsaturated Fatty Acids (2012, neutral): “the brain of AD patients [153].”
• Marine Bioactives as Functional Food Ingredients: Potential to Reduce the Incidence of Chronic Diseases (2011, background): “presented evidence relating to the benefits of n-3 compounds in the treatment of depressive disorders [269,270].”